Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy

BMC Infectious Diseases

Maria Cristina Vidal Pessolani¹  Euzenir Nunes Sarno³  José Augusto da Costa Nery³  Maria Fernanda Miguens Castelar Pinheiro²  Ximena Illarramendi³  Mariana Andrea Hacker³  Luciana Silva Rodrigues¹ 

[1] Laboratory of Cellular Microbiology, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil;Sérgio Franco Laboratory, Rio de Janeiro, RJ, Brazil;Leprosy Laboratory, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil

关键词: Immune-inflammatory response;    Neuroendocrine system;    Biomarker;    Mycobacterium leprae;    Leprosy reactions;    IGFBP-3;    IGF-I;    Leprosy;   

Others  :  1175510
DOI  :  10.1186/1471-2334-11-339

 received in 2011-06-21, accepted in 2011-12-13,  发布年份 2011

【 摘 要 】

Background

Caused by Mycobacterium leprae (ML), leprosy presents a strong immune-inflammatory component, whose status dictates both the clinical form of the disease and the occurrence of reactional episodes. Evidence has shown that, during the immune-inflammatory response to infection, the growth hormone/insulin-like growth factor-I (GH/IGF-I) plays a prominent regulatory role. However, in leprosy, little, if anything, is known about the interaction between the immune and neuroendocrine systems.

Methods

In the present retrospective study, we measured the serum levels of IGF-I and IGBP-3, its major binding protein. These measurements were taken at diagnosis in nonreactional borderline tuberculoid (NR BT), borderline lepromatous (NR BL), and lepromatous (NR LL) leprosy patients in addition to healthy controls (HC). LL and BL patients who developed reaction during the course of the disease were also included in the study. The serum levels of IGF-I, IGFBP-3 and tumor necrosis factor-alpha (TNF-α) were evaluated at diagnosis and during development of reversal (RR) or erythema nodosum leprosum (ENL) reaction by the solid phase, enzyme-labeled, chemiluminescent-immunometric method.

Results

The circulating IGF-I/IGFBP-3 levels showed significant differences according to disease status and occurrence of reactional episodes. At the time of leprosy diagnosis, significantly lower levels of circulating IGF-I/IGFBP-3 were found in NR BL and NR LL patients in contrast to NR BT patients and HCs. However, after treatment, serum IGF-I levels in BL/LL patients returned to normal. Notably, the levels of circulating IGF-I at diagnosis were low in 75% of patients who did not undergo ENL during treatment (NR LL patients) in opposition to the normal levels observed in those who suffered ENL during treatment (R LL patients). Nonetheless, during ENL episodes, the levels observed in RLL sera tended to decrease, attaining similar levels to those found in NR LL patients. Interestingly, IGF-I behaved contrary to what was observed during RR episodes in R BL patients.

Conclusions

Our data revealed important alterations in the IGF system in relation to the status of the host immune-inflammatory response to ML while at the same time pointing to the circulating IGF-I/IGFBP-3 levels as possible predictive biomarkers for ENL in LL patients at diagnosis.

【 授权许可】

   
2011 Rodrigues et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]WHO: Global leprosy situations, 2011. Wkly Epidemiol Rec 2011, 86:389-400.
• [2]Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL: The continuing Challenges of Leprosy. Clin Microbiol Rev 2006, 19:338-381.
• [3]Ridley DS, Jopling WH: Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966, 34:255-273.
• [4]Walker SL, Nicholls PG, Butlin CR, Nery JAC, Roy HK, Rangel E, Sales AM, Lockwood DNJ: Development and Validation of a Severity Scale for Leprosy Type 1 Reactions. PLoS Negl Trop Dis 2008, 2:e351.
• [5]Van Brakel WH, Khawast IB, Lucas SB: Reactions in leprosy: a epidemiological study of 386 patients in West Nepal. Lepr Rev 1994, 65:190-203.
• [6]Nery JA, Vieira LM, de Mattos HJ, Sarno EN: Reactional states in multibacilary Hansen disease patients during multidrug therapy. Rev Inst Med Trop São Paulo 1998, 40:363-370.
• [7]Borghetti P, Saleri R, Mocchegiani E, Corradi A, Martelli P: Infection, immunity and the neuroendocrine response. Vet Immunol Immunopathol 2009, 130:141-162.
• [8]Pérez AR, Bottasso O, Savino W: The impact of infectious diseases upon neuroendocrine circuits. Neuroimmunomodulation 2009, 16:96-105.
• [9]Mesotten D, Van den Berghe G: Changes within the growth hormone/insulin-like growth factor I/IGF binding protein axis during critical illness. Endocrinol Metab Clin North Am 2006, 35:793-805.
• [10]Agha A, Monson JP: Modulation of glucocorticoid metabolism by growth hormone - IGF-1 axis. Clin Endocrionol 2007, 66:459-465.
• [11]Clemmons DR: Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nature 2007, 6:821-833.
• [12]Baxter RC: Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000, 278:967-976.
• [13]Leal AM, Foss NT: Endocrine dysfunction in leprosy. Eur J Clin Microbiol Infect Dis 2009, 28:1-7.
• [14]Rosario PW: Normal values of serum IGF-1in adults: results from a Brazilian population. Arq Bras Endocrinol Metab 2010, 54:477-481.
• [15]Van Buul-Offers SC, Kooijman R: The role of growth hormone and insulin-like growth factors in the immune system. Cell Mol Life Sci 1998, 54:1083-1094.
• [16]Kooijman R, Coppens A: Insulin-like Growth Factor-I stimulates IL-10 production in human T cells. J Leukoc Biol 2004, 76:862-867.
• [17]Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al.: Clinical course of erythema nodosum leprosum: a 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 2006, 74:868-879.
• [18]Guerra JG, Penna GO, de Castro LCM, Martelli CMT, Stefani MMA, Costa MB: Erythema nodosum leprosum case series report: clinical profile, immunological basis and treatment implemented in health services. Rev Soc Bras Med Trop 2004, 37:384-390.
• [19]Sarno EN, Grau GE, Vieira LMM, Nery JA: Serum levels of tumor necrosis factor-alpha and interleukin-1β during leprosy reactional states. Clin Exp Immunol 1991, 84:103-108.
• [20]Lyer A, Hatta M, Usman R, Luiten S, Oskam L, Faber W, et al.: Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin Exp Immunol 2007, 150:210-216.
• [21]Venters HD, Dantzer R, Kelly KW: A New Concept in Neurodegeneration: TNF-α is a Silencer of Survival Signals. T Neurosci 2000, 23:175-180.
• [22]Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, et al.: Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis 2007, 44:33-40.
• [23]Moubasher AD, Kamel NA, Zedan H, Raheem DD: Cytokines in leprosy, I. Serum cytokine profile in leprosy. Int J Dermatol 1998, 37:733-740.
• [24]Belgaumkar VA, Gokhale NR, Mahajan PM, Bharadwaj R, Pandit DP, Deshpande S: Circulating cytokine profile in leprosy patients. Lepr Rev 2007, 78:223-230.
• [25]Timmins AC, Cotterill AM, Hughes SC, Holly JM, Ross RJ, Blum W, Hinds CJ: Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med 1996, 24:1460-1466.
• [26]Heemskerk VH, Daemen MA, Buurman WA: Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev 1999, 10:5-14.
• [27]Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6:813-822.
• [28]Rey AD, Mahuad CV, Bozza VV, Bogue C, Farroni MA, Bay ML, et al.: Endocrine and cytokine responses in humans with pulmonary tuberculosis. Brain Behav Immun 2007, 21:171-179.
• [29]Lima MC, Pereira GM, Rumjanek FD, Gomes HM, Düppre N, Sampaio EP, et al.: Immunological cytokine correlates of prospective immunity and pathogenesis in leprosy. Scand J Immunol 2000, 51:419-428.
• [30]Stefani MM, Guerra JG, Sousa ALM, Costa MB, Oliveira MLW, Martelli CT, Scollard DM: Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. BMC Infect Dis 2009, 9:75-82. BioMed Central Full Text
• [31]Anderson AK, Chaduvula M, Atkinson SE, Khanolkar-Young S, Jain S, Suneetha L, Suneetha S, et al.: Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun 2005, 73:3725-3733.
• [32]Yamamura M, Wang XH, Ohmen JD, Uyemura K, Rea TH, Bloom BR, et al.: Cytokine patterns of immunologically mediated tissue damage. J Immunol 1992, 149:1470-1475.